Actinium Pharmaceuticals Grants 3,000-Share Stock Option to New Hire

Summary

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on October 30, 2026 that it has granted a non‑qualified stock option to a newly hired non‑executive employee. The option allows purchase of 3,000 shares at $1.40 per share, the closing price on the grant date.

Details of the Award

• Grant date: October 26, 2026
• Shares: 3,000
• Exercise price: $1.40 per share
• Term: 10 years
• Vesting schedule: 28 % on the first anniversary of the grant; the remaining 72 % vest in 2 % monthly installments over the next 36 months
• Condition: Vesting is contingent on continued employment through each vesting date
• Plan: Award granted outside the 2019 Stock Plan under Section 711(a) of the NYSE American Company Guide

Company Context

Actinium focuses on targeted radiotherapies for solid tumors and hematologic malignancies. Its pipeline includes:

• ATNM‑400 – a novel antigen‑targeting agent in Phase 1 for metastatic castration‑resistant prostate cancer
• Actimab‑A – a backbone therapy for acute myeloid leukemia, advancing to Phase 2/3
• Iomab‑B / Iomab‑ACT – conditioning agents for bone‑marrow transplant and cell/gene therapy

Actinium holds roughly 250 patents, including cyclotron‑based production of Ac‑225.

Practical Implications

The grant signals Actinium’s commitment to attracting and retaining talent critical for its research and development pipeline. Investors can monitor the company’s SEC filings for updates on the award’s performance and any future equity incentives.

How to Verify

• Check the company’s Form 8‑K filed on the grant date
• Review the 2026 Employment Inducement Award Plan for terms
• Confirm the share price on October 26, 2026 via NYSE American closing data

Forward‑Looking Statements

The release contains forward‑looking statements about future performance and regulatory approvals. These are subject to risks and uncertainties described in Actinium’s SEC filings.